Dostarlimab vs placebo after chemoradiation for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This study tests whether the immunotherapy drug dostarlimab, given after standard chemoradiation, can keep advanced head and neck cancer from coming back. It is for people who have not had surgery and whose tumors are PD-L1 positive.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced head and neck cancer (mouth, throat, or voice box) that cannot be removed with surgery.
- You completed chemotherapy (cisplatin) with radiation and your cancer did not spread to distant body parts.
- Your tumor tested positive for PD-L1 (a protein that helps the immune system target cancer).
- You are well enough to be up and about (ECOG score 0 or 1).
- You have not had previous immunotherapy or certain other cancer treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (GSK5764227) for head and neck cancer that has spread or come back. It looks at your tumor's biomarkers to understand why some people respond to treatment. You may need to have had certain prior treatments depending on which group you join.
This trial looks at whether giving an immunotherapy drug (a PD-1 inhibitor) after surgery is better than giving radiation therapy for people with advanced head and neck cancer who had a complete response to chemotherapy and immunotherapy before surgery. The goal is to prevent the cancer from coming back.
This trial is for people with advanced head and neck cancer who had good response to chemotherapy plus immunotherapy before surgery. It compares two different follow-up treatments: more immunotherapy or radiation therapy to help prevent cancer from coming back.
This trial tests if adding immunotherapy after standard chemoradiation helps prevent cancer from returning in people with high-risk head and neck cancer. It is for those who have completed surgery and have certain high-risk features.
This Phase 2 study tests whether adding dostarlimab (an immunotherapy medicine) to radiation after surgery can lower cancer returning and improve outcomes. It’s for people with certain endometrial cancers found to have specific genetic/molecular changes and who have stage III/IVA disease after surgery.
This trial tests whether pembrolizumab (an immunotherapy drug) works better than the usual chemo plus radiation after surgery for cancer that has come back in the head and neck area. It may help reduce cancer returning or spreading by using your immune system, but eligibility depends on how the cancer came back and your prior treatments.
Hear when a new Neoplasms, Head and Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.